Spyre Therapeutics Inc
SYRE
NASDAQ
Biotechnology
$103.63
USD
+1.78 (+1.75%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $8.97B
Volume 559.5K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-178.92M
TTM
+13.5%
YoY
Operating Cash Flow
$-208.94M
TTM
-35.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 11.8 | 11.6 | 12.5 | 15.2 | 16.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 51.9 | 56.9 | 57.2 | 75.6 | 81.6 |
Operating Income | -51.9 | -56.9 | -57.2 | -75.6 | -81.6 |
EBITDA | -51.9 | -56.9 | -57.2 | -75.6 | -81.6 |
Other Income / Expense | 9.3 | 40.3 | -12.5 | -0.4 | 35.4 |
Total Other Income / Expense | 15.2 | 45.7 | -5.4 | 6.6 | 45.4 |
Income Before Income Taxes | -36.7 | -11.2 | -62.5 | -69.0 | -36.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -36.7 | -11.2 | -62.5 | -69.0 | -36.2 |
Consolidated Net Income / Loss | -36.7 | -11.2 | -62.5 | -69.0 | -36.2 |
Net Income Attributable to Common Shareholders | -29.6 | -9.0 | -51.8 | -58.2 | -30.9 |
Basic EPS | -$0.49 | -$0.15 | -$0.69 | -$0.74 | -$0.36 |
Diluted EPS | -$0.49 | -$0.15 | -$0.69 | -$0.74 | -$0.36 |
Basic Shares Outstanding | 60.3M | 60.4M | 75.2M | 78.5M | 84.7M |
Diluted Shares Outstanding | 60.3M | 60.4M | 75.2M | 78.5M | 84.7M |